Opinion|Videos|February 3, 2025

Real-World Challenges to Providing Evidence-Based Care for Atopic Dermatitis

Panelists discuss the 2023 American Academy of Allergy, Asthma & Immunology/ American College of Allergy, Asthma & Immunology (AAAAI/ACAAI) Joint Task Force guidelines, highlighting treatment options with strong recommendations and high certainty of evidence, including biologics/monoclonal antibodies (dupilumab, tralokinumab, lebrikizumab) and Janus kinase (JAK) inhibitors (abrocitinib, baricitinib, upadacitinib) for atopic dermatitis management.

Episodes in this series

Video content above is prompted by the following:

  • 2023 AAAAI/ACAAI Joint Task Force Practice Parameters and Guidelines (Ann Allergy Asthma Immunol 2024;132:274-312).
  • Discuss the treatment options with strong recommendations and high certainty of evidence.
  • Biologics/monoclonal antibodies: dupilumab, tralokinumab, lebrikizumab
  • JAK inhibitors: abrocitinib, baricitinib, upadacitinib

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Subscribe Now!

Related Content

Latest CME

Burst CME: Targeted Therapy for Optimal Psoriasis Management
Video

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Tina Bhutani, MD

View more
Cases and Conversations™: A Horizon View of Continuous Monitoring Systems for Diabetes Management
Video

Cases and Conversations™: A Horizon View of Continuous Monitoring Systems for Diabetes Management

Diana Isaacs, PharmD, BCPS, BC-ADM, BCACP, CDCES, FADCES, FCCP; Anders Carlson, MD; Jennifer B. Green, MD

View more